Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANI PHARMACEUTICALS, INC.

(ANIP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ANI Pharmaceuticals : Says FDA Accepts for Review Its Supplemental New Drug Application for Purified Cortrophin Gel

08/31/2021 | 07:48am EDT


© MT Newswires 2021
All news about ANI PHARMACEUTICALS, INC.
09/20ANI PHARMACEUTICALS : to Present at Cantor Virtual Global Healthcare Conference 2021
BU
09/17ANI PHARMACEUTICALS : Launches Generic Hypertension Drug
MT
09/17ANI PHARMACEUTICALS : Announces Launch of Nebivolol Tablets
BU
09/17ANI Pharmaceuticals, Inc. Announces Launch of Nebivolol Tablets
CI
08/31ANI PHARMACEUTICALS : Says FDA Accepts for Review Its Supplemental New Drug Application fo..
MT
08/31ANI PHARMACEUTICALS : FDA Accepts Application for Cortrophin Gel Revival
DJ
08/31ANI PHARMACEUTICALS : Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental Ne..
BU
08/31Ani Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental N..
CI
08/06ANI PHARMACEUTICALS : Posts Lower Q2 Earnings, Revenue Increases
MT
08/06ANI PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
More news
Analyst Recommendations on ANI PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 210 M - -
Net income 2021 -15,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -29,0x
Yield 2021 -
Capitalization 446 M 446 M -
Capi. / Sales 2021 2,13x
Capi. / Sales 2022 1,83x
Nbr of Employees 369
Free-Float 77,0%
Chart ANI PHARMACEUTICALS, INC.
Duration : Period :
ANI Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANI PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 36,86 $
Average target price 45,00 $
Spread / Average Target 22,1%
EPS Revisions
Managers and Directors
Nikhil Lalwani President, Chief Executive Officer & Director
Stephen P. Carey Chief Financial Officer, Secretary & VP
Patrick D. Walsh Chairman
James G. Marken Senior VP-Operations & Product Development
Robert E. Brown Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANI PHARMACEUTICALS, INC.26.93%446
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979